Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Click to increase image sizeClick to decrease image size

Acknowledgments

Obinutuzumab was supplied by Roche and Bendamustine was provided by Mundipharma during the trial.

Disclosure statement

Nadine Kutsch Grants: Gilead, AstraZeneca. Payment for lectures including service on speakers bureaus: AstraZeneca, Roche. Honoraria: AstraZeneca, BMS. Travel support from AstraZeneca, Celgene, Gilead, Janssen.

Emily Eva Holmes no conflict of interest

Sandra Robrecht Honoraria: AstraZeneca

Gudrun Schüler no conflict of interest

Ursula Vehling-Kaiser no conflict of interest

Thomas Decker Consultancy and payment for lectures including service on speakers bureaus: Novartis

Sigrun Müller-Hagen no conflict of interest

Karin Heinisch no conflict of interest

Sebastian Böttcher Honoraria: AbbVie, AstraZeneca, Janssen, Roche, Sanof. Consulting or Advisory Role: AbbVie, AstraZeneca, Janssen, Roche, Sanofi. Research Funding: Janssen

Matthias Ritgen Consulting fee or Honorarium: AbbVie, AstraZeneca, Janssen, Roche. Travel support: AbbVie, AstraZeneca, Janssen, Roche. Patents: EuroFlow MRD Diagnostics

Karl-Anton Kreuzer Consultancy: Mundipharma, Roche. Grants Mundipharma, Roche. Payment for lectures including service on speakers bureaus Mundipharma, Roche

Stephan Stilgenbauer fees for consulting, drug/equipment supplied by the entity, travel paid by the entity, writing assistance: AbbVie, AstraZeneca, Celgene, Gilead, Roche, Janssen, Novartis, Morphosys

Anna Maria Fink Grants: AstraZeneca, Celgene. Payment for lectures including service on speakers bureaus: AstraZeneca

Kirsten Fischer Honoraria: AbbVie, Roche. Travel grants: Roche

Barbara Eichhorst Research funding: AbbVie; AstraZeneca, BeiGene; Gilead, Janssen, Roche. Consulting fee or honorarium: AbbVie, AstraZeneca, BeiGene, MSD, Roche. Travel Support: BeiGene. Payment for lectures including service on speakers bureaus: AbbVie, AstraZeneca, BeiGene, MSD, Roche

Michael Hallek Hononraria (speaker's bureau and/or advisory/or advisory board): Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie, AstraZeneca. Grants: Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie, AstraZenec

Clemens-Martin Wendtner Consultancy: AbbVie, AstraZeneca, BeiGene, Janssen, Mundipharma, Roche

Additional information

Funding

This study was supported by research funding from F. Hoffmann-La Roche Ltd., Basel, Switzerland.